BioAge Labs, Inc. $BIOA Shares Sold by Cormorant Asset Management LP

Cormorant Asset Management LP lowered its position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) by 4.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,040,605 shares of the company’s stock after selling 100,000 shares during the quarter. BioAge Labs makes up about 1.2% of Cormorant Asset Management LP’s holdings, making the stock its 18th largest holding. Cormorant Asset Management LP owned 5.69% of BioAge Labs worth $26,997,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of BioAge Labs in the second quarter valued at approximately $64,000. Marshall Wace LLP grew its position in shares of BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after purchasing an additional 173,388 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of BioAge Labs in the second quarter valued at approximately $182,000.

Wall Street Analysts Forecast Growth

BIOA has been the subject of a number of analyst reports. Citigroup upped their price target on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Roth Mkm initiated coverage on BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price target for the company. Finally, Needham & Company LLC began coverage on BioAge Labs in a research report on Friday, March 27th. They issued a “buy” rating and a $50.00 price target for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and an average price target of $43.50.

BioAge Labs Stock Performance

Shares of BioAge Labs stock opened at $19.99 on Thursday. The firm has a market capitalization of $888.56 million, a price-to-earnings ratio of -8.33 and a beta of 0.94. BioAge Labs, Inc. has a fifty-two week low of $4.07 and a fifty-two week high of $24.00. The stock has a 50 day moving average of $17.35 and a 200 day moving average of $17.31.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Analysts forecast that BioAge Labs, Inc. will post -2.68 EPS for the current year.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.